150 related articles for article (PubMed ID: 12228197)
1. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Eder JP; Supko JG; Clark JW; Puchalski TA; Garcia-Carbonero R; Ryan DP; Shulman LN; Proper J; Kirvan M; Rattner B; Connors S; Keogan MT; Janicek MJ; Fogler WE; Schnipper L; Kinchla N; Sidor C; Phillips E; Folkman J; Kufe DW
J Clin Oncol; 2002 Sep; 20(18):3772-84. PubMed ID: 12228197
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of recombinant human endostatin in patients with advanced solid tumors.
Herbst RS; Hess KR; Tran HT; Tseng JE; Mullani NA; Charnsangavej C; Madden T; Davis DW; McConkey DJ; O'Reilly MS; Ellis LM; Pluda J; Hong WK; Abbruzzese JL
J Clin Oncol; 2002 Sep; 20(18):3792-803. PubMed ID: 12228199
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
Thomas JP; Arzoomanian RZ; Alberti D; Marnocha R; Lee F; Friedl A; Tutsch K; Dresen A; Geiger P; Pluda J; Fogler W; Schiller JH; Wilding G
J Clin Oncol; 2003 Jan; 21(2):223-31. PubMed ID: 12525513
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin.
Hu B; Zhu HW; Zhu LP; Li C; Rong ZG; Xu JM; Wu ZW; Wang JJ; Xu GX
Acta Pharmacol Sin; 2008 Nov; 29(11):1357-69. PubMed ID: 18954531
[TBL] [Abstract][Full Text] [Related]
5. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant human endostatin on a human neuroblastoma xenograft.
Kuroiwa M; Ikeda H; Hongo T; Tsuchida Y; Hirato J; Kaneko Y; Suzuki N; Obana K; Makino SI
Int J Mol Med; 2001 Oct; 8(4):391-6. PubMed ID: 11562777
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Kulke MH; Bergsland EK; Ryan DP; Enzinger PC; Lynch TJ; Zhu AX; Meyerhardt JA; Heymach JV; Fogler WE; Sidor C; Michelini A; Kinsella K; Venook AP; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3555-61. PubMed ID: 16877721
[TBL] [Abstract][Full Text] [Related]
8. Assessment of antiangiogenic effect using 99mTc-EC-endostatin.
Yang DJ; Kim KD; Schechter NR; Yu DF; Wu P; Azhdarinia A; Roach JS; Kalimi SK; Ozaki K; Fogler WE; Bryant JL; Herbst R; Abbruzzes J; Kim EE; Podoloff DA
Cancer Biother Radiopharm; 2002 Apr; 17(2):233-45. PubMed ID: 12030117
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma.
Ye C; Feng C; Wang S; Liu X; Lin Y; Li M
Endocrinology; 2002 Sep; 143(9):3522-8. PubMed ID: 12193566
[TBL] [Abstract][Full Text] [Related]
11. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS; Mullani NA; Davis DW; Hess KR; McConkey DJ; Charnsangavej C; O'Reilly MS; Kim HW; Baker C; Roach J; Ellis LM; Rashid A; Pluda J; Bucana C; Madden TL; Tran HT; Abbruzzese JL
J Clin Oncol; 2002 Sep; 20(18):3804-14. PubMed ID: 12228200
[TBL] [Abstract][Full Text] [Related]
12. Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial.
Wang X; Shi Y; Jia Y; Zhao W; Zhang L; Bai G; Ren Y; Chen YZ; Tong Z
Technol Cancer Res Treat; 2021; 20():15330338211064434. PubMed ID: 34931914
[No Abstract] [Full Text] [Related]
13. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
14. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment.
Xu F; Ma Q; Sha H
Crit Rev Ther Drug Carrier Syst; 2007; 24(5):445-92. PubMed ID: 18197781
[TBL] [Abstract][Full Text] [Related]
15. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
Mundhenke C; Thomas JP; Wilding G; Lee FT; Kelzc F; Chappell R; Neider R; Sebree LA; Friedl A
Clin Cancer Res; 2001 Nov; 7(11):3366-74. PubMed ID: 11705849
[TBL] [Abstract][Full Text] [Related]
16. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
17. Antitumor interaction of short-course endostatin and ionizing radiation.
Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of tissue endostatin in human malignant gliomas.
Morimoto T; Aoyagi M; Tamaki M; Yoshino Y; Hori H; Duan L; Yano T; Shibata M; Ohno K; Hirakawa K; Yamaguchi N
Clin Cancer Res; 2002 Sep; 8(9):2933-8. PubMed ID: 12231538
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
Hansma AH; Broxterman HJ; van der Horst I; Yuana Y; Boven E; Giaccone G; Pinedo HM; Hoekman K
Ann Oncol; 2005 Oct; 16(10):1695-701. PubMed ID: 16012180
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.
Miyashita M; Tajiri T; Yanagi K; Shimizu T; Futami R; Sasajima K; Tokunaga A
Hepatogastroenterology; 2003; 50(50):308-9. PubMed ID: 12749209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
